Which are the causes of Pityriasis Rubra Pilaris?

The exact cause of Pityriasis Rubra Pilaris (PRP) remains unknown, though it is generally categorized into familial (inherited) and acquired (non-hereditary) forms. Research suggests that Pityriasis Rubra Pilaris involves a combination of genetic predispositions in the familial type and potential immune system dysregulation or environmental triggers in the acquired types.

Is Pityriasis Rubra Pilaris a genetic condition?

The role of genetics in Pityriasis Rubra Pilaris depends on the specific clinical classification. The familial form of Pityriasis Rubra Pilaris (Type V) is typically inherited in an autosomal dominant pattern. In these cases, a mutation in the CARD14 gene is often identified. This gene provides instructions for making a protein that helps regulate the body’s inflammatory response. When this gene is mutated, it can lead to an overactive immune response in the skin, resulting in the characteristic scaling and redness seen in Pityriasis Rubra Pilaris. However, most cases of the disease are "acquired," meaning they occur sporadically in individuals with no known family history, suggesting that genetic factors are not the sole cause for the majority of patients.

What are the suspected triggers for acquired Pityriasis Rubra Pilaris?

For the vast majority of people, Pityriasis Rubra Pilaris is considered an acquired condition, meaning it is not passed down through families. While the precise trigger for the onset of acquired Pityriasis Rubra Pilaris is often difficult to pinpoint, researchers have investigated several potential contributors:

• Immune System Dysregulation: Many experts believe an underlying autoimmune mechanism may trigger the condition, where the body’s immune system mistakenly attacks healthy skin cells.


• Infections: Some patients report the onset of symptoms following a viral or bacterial infection, suggesting that an immune response to a pathogen might act as a "trigger" in susceptible individuals.


• Medication Reactions: In rare instances, certain medications have been associated with the development of symptoms similar to Pityriasis Rubra Pilaris, though this is considered a secondary effect rather than a primary cause.


• Metabolic Factors: While not fully understood, some studies explore how metabolic changes might influence skin barrier function and inflammation.

What is the difference between a cause and a risk factor?

In medical research, a "cause" is a direct factor that produces the disease, such as the CARD14 mutation in familial cases. A "risk factor," conversely, is something that increases the likelihood of developing the disease but does not necessarily trigger it directly. For Pityriasis Rubra Pilaris, having a family history is a clear cause for Type V, whereas environmental stressors or immune system variations act as risk factors for the acquired forms. Currently, the medical community is still working to bridge the gap between these risk factors and the biological mechanisms that turn these risks into active skin disease.

What is the current state of research into this condition?

The 96 members of the DiseaseMaps.org community who have shared their experiences reflect the diverse presentation of this condition. Researchers are currently focusing on "omics" studies—genomics and proteomics—to better understand why the skin’s keratinization process goes awry. By studying the inflammatory pathways, scientists hope to develop targeted therapies that address the root cause rather than just managing symptoms.

Next steps

• Consult a board-certified dermatologist who has specific experience diagnosing and treating rare papulosquamous disorders.


• Keep a detailed symptom diary to help your physician identify potential environmental or lifestyle triggers.


• Connect with the DiseaseMaps.org community to share experiences and learn from others living with this rare condition.


• Ask your specialist about clinical registries or research studies that may be open to new participants.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• National Institutes of Health (NIH) Genetic and Rare Diseases Information Center (GARD).


• Orphanet: Portal for rare diseases and orphan drugs.


• Online Mendelian Inheritance in Man (OMIM): Clinical synopsis for Pityriasis Rubra Pilaris.


• Pityriasis Rubra Pilaris (PRP) Alliance: Patient-focused research and advocacy resources.